Full-Time

Medical Science Liaison

Posted on 7/4/2026

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

Washington, DC, USA

Remote

Remote role; up to 60% travel may be required.

Category
Biology & Biotech (1)

Get referred to Mallinckrodt

See people who can refer or advise you

Requirements
  • Advanced scientific degree (MD, OD, PhD, PharmD) or clinical degree (NP, PA); or equivalent clinical experience (e.g., RN, RT) if appropriate
  • 2+ years’ experience in the pharmaceutical industry, other healthcare environment or equivalent experience
  • Ability to effectively communicate scientific content through face-to-face individual meetings, small group interactions, and in writing
  • Effective collaboration with internal departments is essential, and the ability to work cohesively as a strong team player
  • Demonstrate independence, adaptability, and strong interpersonal skills while showcasing problem-solving abilities, strategic thinking, and a patient-centered approach
  • Be committed to full compliance with all company SOPs, regulatory requirements, and applicable laws including PhRMA guidelines for field-based personnel.
  • Must possess a valid driver’s license
Responsibilities
  • Develop relationships with focus KOLs in their assigned territory through engaging in scientific exchange
  • Engage in peer-to-peer scientific dialogue effectively communicating scientific, medical, technical, or product (reactive) content
  • Support HCP field education, training, and safe use of drugs or biologics.
  • Assess KOL alignment with the key scientific discussion topics to inform territory and medical strategy
  • Identify KOL Advocates and Collaborators within your assigned territory
  • Compliantly support company sponsored research, investigator-initiated research, external collaborative research, and publications associated with Keenova Therapeutics product(s)
  • Stay abreast of emerging scientific literature/clinical data and translate to applicable knowledge.
  • Ensure appropriate communication of clinical and scientific information regarding FDA approved and pipeline products in a timely, ethical, and customer-focused manner with support of your manager
  • Respond to MIRFs with an initial contact within 2 days and a full answer within 3 weeks (when a standard response letter doesn’t exist)
  • Collect scientific and clinical insights based on scientific information/clinical data sharing to optimize medical communications and coordinated strategy and tactics across the organization.
  • Respond to all requests for directed insights within the expected timeframe
  • Participate in advisory boards as requested
  • Contributes scientific content and/or helps create materials in support of a project or initiative
  • Participates in team calls, projects, and activities
  • Collaborate with MSL colleagues
  • Understand and operate in alignment with the Keenova Therapeutics Values and Leadership Framework
Desired Qualifications
  • Prior experience in Hepatology, Nephrology, or Transplantation
  • Demonstrated ability to access and develop relationships with external stakeholders
  • Thorough knowledge of medicine, treatment guidelines, clinical research processes, customer strategies, and FDA promotional guidelines, regulations, and ethical guidelines

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Rare-disease and autoimmune products support premium pricing and physician-driven demand.
  • US manufacturing strengthens supply-chain appeal for hospitals and policymakers.
  • Post-Endo portfolio breadth expands cross-selling across branded therapeutics and generics.

What critics are saying

  • Specialty generics face commoditization and persistent margin compression.
  • Legacy opioid liabilities still threaten cash flow and future restructuring.
  • Narrow product concentration creates sharp revenue loss from exclusivity or formulary setbacks.

What makes Mallinckrodt unique

  • Specialty portfolio spans autoimmune, rare disease, neonatal respiratory, and critical care therapies.
  • Keenova Therapeutics and Par Health create clearer branded and generics focus.
  • Dublin headquarters with U.S. operations supports global reach and domestic execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE